Blog Post

Pharmaceutical industry at risk from Brexit

Pharmaceuticals are a hugely important industry for the EU and the UK. The sector creates thousands of jobs, billions of euros in exports, and is Europe’s most research-intense industry. But will Brexit mean for pharma? Border delays, disruption to R&D and regulatory divergence all pose hazards.

By: Date: May 31, 2017 Topic: European Macroeconomics & Governance

Despite numerous debates about the impact of Brexit, the pharmaceutical industry seems to be less eye-catching than other sectors like the manufacturing supply chain and financial services. However, pharmaceuticals are one of the EU’s most important and fastest-growing industries, and they benefit greatly from EU integration.

Pharmaceutical in the EU has increased from €125 billion to €225 billion over the past fifteen years. Employment in the sector also grew dramatically from 535000 to 725000. The pharmaceuticals sector has also become very advantageous for the EU. Exports of pharmacy products have more than tripled over the past fifteen years, with most of these gains obtained from extra-EU transactions. Pharmaceuticals are also the third largest industry in the UK, contributing 10 percent of the UK’s GDP, with an employment of 73000 people and a trade surplus of €3.3 billion.

Table 1: The rapid growth of the European pharmaceutical industry

INDUSTRY (EFPIA total) 2000 2010 2014 2015
Production 125,316 199,400 221,088 225,000
Exports 90,935 276,357 324,452 361,500
Imports 68,841 204,824 251,427 275,000
Trade balance 22,094 71,533 73,025 86,500
R&D expenditure 17,849 27,920 30,887 31,500
Employment 534,882 670,088 723,448 725,000
R&D employment 88,397 117,035 118,052 118,000

 

Source: “The pharmaceutical industry in figures”, 2016, European federation of pharmaceutical industries and associations.

The rapid advance of the pharmaceuticals sector over the past decade can be closely associated with the integration of the EU trade chain. In 2016, around 67% of the EU’s exports of its products were intra-EU exports; 52% of the EU’s imports of its products were intra-EU imports. According to EFPIA figures, among the EU member states the UK is undoubtedly a key player, constituting 10% of the EU’s total production and employment. Moreover, the UK runs a trade deficit of €114 billion against the other EU27 countries, implying that it is a major destination for EU pharmaceutical products.

Non-tariff barriers such as the possible establishment of physical border could have negative effects on pharmaceutical trade

Fortunately, the EU has long adopted zero most-favored-nation tariffs even for international extra-EU transactions for pharmaceutical products. So the worst scenario, even in a hard Brexit where the EU and UK treat each other in the WTO multilateral framework manner, would not add a specific tariff burden on pharmaceutical trade.

However, tariffs are not the only barrier to trade. There is also a possibility that other types of non-tariff barriers could be created to hamper pharmaceutical trade. In particular, with the strengthening of immigration control, border checks might be resumed which could create delays in transferring pharmaceutical products to/from the UK. Longer lead times and increased paperwork caused by these customs bottlenecks could affect service levels and margins – especially for pharmaceutical products, which have a short shelf life. Evidence has shown that, for time-sensitive industries, every 1 hour of customs delay adds 0.8 percentage points to the ad valorem trade-cost rate and leads to 5% less trade. This means that perishable pharmaceutical products are likely to cost more for UK residents, especially in the case of emergency.

The establishment of a physical border also matters particularly for Ireland. Ireland is the only country that shares a land border with the UK. Although it is hard to say what will eventually happen in the event of Brexit until the final post-Brexit model is determined, the risk has been mounting since Theresa May’s report signaling a hard Brexit. Establishing an Irish-Irish border would mean that Irish pharmaceutical products need to go across the UK border twice before entering the rest of the EU. One solution to avoid this additional processing cost is to construct a common border for two countries, which was already the case for passengers from 16 countries such as China and India to enter the region. But that undoubtedly means additional costs for Irish pharmaceutical consumers.

Disruption of research and development (R&D) activities

One of the key characteristics of the pharmaceutical industry is its high intensity in research and development. Figure 3 shows that the pharmaceutical and biotechnology sector accounts for the highest R&D intensity in the EU, even higher than the software and computer services sector. Eurostat data also indicates that the pharmaceutical industry has the highest added-value per person employed.

Within the pharmaceutical industry, UK has long been a center for research and development (R&D) activities. In 2015, it contributed approximately 20% of the EU’s total R&D, only slightly lower than Germany and France. As Maria Demertzis and Enrico Nano highlight, these research and development activities rely on two key factors: skilled labour supply and research funding. Both factors could be at risk in the post-Brexit era. For the former, the UK has attracted a large number of skilled workers from abroad, most of which are EU citizens. For the latter, the UK gains more research funding in the current system than any other country. Therefore, Brexit could undoubtedly have a negative impact for both factors in the pharmacy industry.

 

In addition, research and development in the pharmaceutical industry rely on protections on trademarks and associated rights, which are currently covered by EU laws. The future of these activities after Brexit depends on the intellectual protection coordination arrangement between the EU and UK. The further the arrangement goes away from the current system, the more challenging the future will be.

Regulatory segmentation

The unification of the regulatory framework on product standards has eased entry barriers for pharmaceutical companies in the EU. For example, the current product standard in the European Economic Area (EEA) is authorised by the London-based European Medicines Agency (EMA), meaning that all drugs approved by EMA are automatically granted access to the UK’s market. If the UK’s post-Brexit relationship with the EU does not include a shared regulatory framework, access to the both markets would be subject to additional process. Any disruption is likely to lead to a geographic reallocation of the pharmaceutical industry. This can be detrimental for the UK but could be an opportunity for substitutive countries taking on this business.

The EMA being in London is also the reason why a number of influential pharmacy companies choose to locate their European headquarters in the UK. Ironically, even the European Medicines Agency (EMA) may find itself in an awkward situation after Brexit, because it is currently located in Canary Wharf, London. It is highly unlikely that the UK can keep the medical authority, and the long-term benefits to the UK from proximity to the EMA will also be lost.

Conclusions

The impact of Brexit on the European and British pharmaceutical industry will go far beyond the simple trade analysis based on tariffs but to more non-tariff aspects. The establishment of a physical border will cause delay in transportation not only for the UK but also Ireland. This may increase the cost of pharmaceutical products especially those with short expiration date.

Moreover, a UK outside of the EU might find it difficult to attracted skilled experts for the industry, lose research funding supported by the EU, and face barriers accessing the EU27 market. For the rest of the EU, Brexit could also cause similar additional costs on the whole, but given its larger economic size than the UK, the loss would also be smaller. For some EU countries, if they can seize the opportunity to take on UK business, or become the new location for the EMA, there is a chance to benefit despite the general loss in the EU.

Nonetheless, the best strategy to reserve benefits for both the EU and UK is still to maintain existing relationship between two parties on all the related aspects. But this seems to be an increasingly challenging task in the likely scenario of hard Brexit.


Republishing and referencing

Bruegel considers itself a public good and takes no institutional standpoint. Anyone is free to republish and/or quote this post without prior consent. Please provide a full reference, clearly stating Bruegel and the relevant author as the source, and include a prominent hyperlink to the original post.

View comments
Read about event

Upcoming Event

Sep
3-4
08:30

Bruegel Annual Meetings 2018

The 2018 Annual Meetings will be held on 3-4 September and will feature sessions on European and global economic governance, as well as finance, energy and innovation.

Speakers: Maria Åsenius, Richard E. Baldwin, Carl Bildt, Maria Demertzis, Lowri Evans, Mariya Gabriel, Péter Kaderják, Joanne Kellermann, Jörg Kukies, Emmanuel Lagarrigue, Philippe Lespinard, Montserrat Mir Roca, Dominique Moïsi, Jean Pierre Mustier, Ana Palacio, Jean Pisani-Ferry, Lucrezia Reichlin, Norbert Röttgen, André Sapir, Jean-Claude Trichet, Johan Van Overtveldt, Martin Sandbu, Margrethe Vestager, Reinhilde Veugelers, Thomas Wieser, Guntram B. Wolff and Georg Zachmann Topic: Energy & Climate, European Macroeconomics & Governance, Finance & Financial Regulation, Global Economics & Governance, Innovation & Competition Policy Location: Brussels Comic Strip Museum, Rue des Sables 20, 1000 Brussels
Read about event More on this topic

Upcoming Event

Oct
3
09:00

International trade and the EU-Japan Economic Partnership Agreement

This event; jointly organised by Bruegel and the Graduate School of Economics, Kobe University, will discuss the EU-Japan trade deal and asses its impact.

Speakers: Marco Chirullo, Gabriel Felbermayr, François Godement, Hiroo Inoue, Sébastien Jean, Yoichi Matsubayashi, Tamotsu Nakamura, André Sapir, Cécile Toubeau, Agata Wierzbowska and Guntram B. Wolff Topic: Global Economics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels
Read about event

Upcoming Event

Oct
11-12
20:00

Policy responses for an EU-MENA shared future

In the third edition of the "Platform for Advanced & Emerging Economies Policy Dialogue" we will discuss trade flows and trade policy between Europe and MENA, integration of developing economies into global value chains, and regional energy relations.

Speakers: Karim El Aynaoui and Guntram B. Wolff Location: Rome
Read article More on this topic More by this author

Opinion

Is Europe America’s Friend or Foe?

Since Donald Trump took office as US president, a new cottage industry in rational theories of his seemingly irrational behavior has developed. On one issue, however, no amount of theorizing has made sense of Trump: his treatment of America's oldest and most reliable ally.

By: Jean Pisani-Ferry Topic: Global Economics & Governance Date: July 30, 2018
Read article More on this topic

Opinion

Europe should avoid a no-deal Brexit

The UK government finally tabled a serious proposal for the country’s future relationship with the European Union (EU). The White Paper puts the ball in the EU court as it now has to say what kind of relationship it wants to establish with its neighbour.

By: Jean Pisani-Ferry, Norbert Röttgen, André Sapir, Paul Tucker and Guntram B. Wolff Topic: European Macroeconomics & Governance Date: July 24, 2018
Read article More on this topic More by this author

Opinion

A Brexit deal is still not achieved

The UK paper should be seriously considered. While it breaks a number of European red-lines, it is also an attempt to solve some issues. The question is whether the EU will be ready to seriously negotiate. Geostrategic considerations suggest that it is time for the EU to do so.

By: Guntram B. Wolff Topic: European Macroeconomics & Governance Date: July 13, 2018
Read about event More on this topic

Past Event

Past Event

Designing a new institutional framework for UK-EU relations

Finding the right way forward for the EU and the UK.

Speakers: Raphael Hogarth, Jill Rutter and Guntram B. Wolff Topic: European Macroeconomics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: July 13, 2018
Read about event More on this topic

Past Event

Past Event

Should we revisit the patent system for pharmaceutical products?

Analysis of the legal issues with the current IP system for regulated market authorisations for pharmaceutical products, as well as its economic effects.

Speakers: Arno Hartmann, Christian Jervelund, Margaret K. Kyle, Roberto Romandini, Bruno van Pottelsberghe, Amaryllis Verhoeven and Reinhilde Veugelers Topic: Innovation & Competition Policy Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: July 9, 2018
Read article More on this topic More by this author

Opinion

Ubu ou Machiavel?

L'administration Trump veut imposer une approche transactionnelle des relations économiques gouvernée par le rapport de force bilatéral en lieu et place du contrat multilatéral. Un défi d'une ampleur inédite pour l'Europe.

By: Jean Pisani-Ferry Topic: Global Economics & Governance Date: July 6, 2018
Read article More on this topic More by this author

Blog Post

US tariffs and China's holding of Treasuries

China has the biggest bilateral trade surplus vis-à-vis the US but is also a top holder of US government bonds. While China has started to counteract US trade tariffs, economists have been discussing the case of China acting on its holdings of US Treasuries. We review recent contributions.

By: Silvia Merler Topic: Global Economics & Governance Date: July 2, 2018
Read article

Blog Post

Trading invisibles: Exposure of countries to GDPR

This blog post identifies provisions of the EU’s General Data Protection Regulation (GDPR) that affect foreign companies, and discusses implications for trade in services with the EU. The authors provide a novel mapping of countries’ relative exposure to these regulations by a) measuring the digital maturity of their service exports to the EU; and b) the share of these exports in national GDP.

By: Sonali Chowdhry and Nicolas Moës Topic: European Macroeconomics & Governance, Global Economics & Governance Date: June 28, 2018
Read about event More on this topic

Past Event

Past Event

Trade war trinity: analysis of global consequences

Analysis of the long-term impact of the trade war and its three key players: EU, US, and China.

Speakers: Alicia García-Herrero, Ignasi Guardans and Carl B Hamilton Topic: Global Economics & Governance Location: Bruegel, Rue de la Charité 33, 1210 Brussels Date: June 28, 2018
Load more posts